Cyclo Therapeutics Inc. (CYTH) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
6714 NW 16TH STREET, SUITE B GAINESVILLE, FL 32653 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 9,247 | 1,543 | 16,613 | 12,846 | 2,784 | 2,217 | |||
| Cash and cash equivalents | 9,247 | 1,543 | 16,613 | 12,846 | 2,784 | 2,217 | |||
| Receivables | 122 | 55 | 539 | 112 | 182 | 37 | |||
| Inventory, net of allowances, customer advances and progress billings | 254 | 254 | 227 | 238 | 243 | 417 | |||
| Inventory | 254 | 254 | 227 | 238 | 243 | 417 | |||
| Prepaid expense | 385 | 101 | 42 | 126 | 137 | ||||
| Other current assets | 18 | ||||||||
| Other undisclosed current assets | 2,310 | 2,205 | 2,015 | 728 | 612 | 80 | |||
| Total current assets: | 12,318 | 4,159 | 19,436 | 14,050 | 3,958 | 2,770 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 891 | 1 | 18 | 34 | 51 | ✕ | |||
| Property, plant and equipment | 38 | 55 | 60 | 54 | 14 | 19 | |||
| Long-term investments and receivables | 7 | 50 | 91 | 130 | |||||
| Accounts and financing receivable, after allowance for credit loss | 7 | 50 | 91 | 130 | |||||
| Prepaid expense | |||||||||
| Total noncurrent assets: | 929 | 57 | 84 | 138 | 155 | 148 | |||
| TOTAL ASSETS: | 13,248 | 4,215 | 19,521 | 14,188 | 4,113 | 2,918 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 7,457 | 3,481 | 3,678 | 3,541 | 3,125 | 1,925 | |||
| Accounts payable | 4,857 | ||||||||
| Accrued liabilities | 1,778 | ||||||||
| Other undisclosed accounts payable and accrued liabilities | 823 | 3,481 | 3,678 | 3,541 | 3,125 | 1,925 | |||
| Debt | 134 | 114 | 16 | ||||||
| Other undisclosed current liabilities | 1,011 | 19 | 17 | ||||||
| Total current liabilities: | 8,468 | 3,481 | 3,831 | 3,673 | 3,141 | 1,925 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 18 | 63 | 36 | ||||||
| Long-term debt, excluding current maturities | 18 | 44 | |||||||
| Liabilities, other than long-term debt | 22 | ||||||||
| Operating lease, liability | 22 | 18 | 36 | ✕ | |||||
| Other undisclosed noncurrent liabilities | (18) | ||||||||
| Total noncurrent liabilities: | 22 | 18 | 63 | 36 | |||||
| Total liabilities: | 8,491 | 3,481 | 3,849 | 3,735 | 3,177 | 1,925 | |||
| Equity | |||||||||
| Equity, attributable to parent | 4,757 | 735 | 15,672 | 10,452 | 936 | 993 | |||
| Preferred stock | |||||||||
| Common stock | 3 | 1 | 1 | 0 | 12 | 9 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (130) | ||||||||
| Additional paid in capital | 88,611 | 64,533 | 64,020 | 44,514 | 26,044 | 18,701 | |||
| Accumulated deficit | (83,857) | (63,799) | (48,348) | (34,062) | (25,120) | (17,588) | |||
| Total equity: | 4,757 | 735 | 15,672 | 10,452 | 936 | 993 | |||
| TOTAL LIABILITIES AND EQUITY: | 13,248 | 4,215 | 19,521 | 14,188 | 4,113 | 2,918 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,076 | 1,376 | 1,586 | 903 | 1,007 | 1,011 | ||
| Cost of revenue | (353) | (541) | (165) | (148) | (168) | (139) | ||
| Cost of goods and services sold | (53) | (13) | (105) | |||||
| Other undisclosed gross profit | 269 | |||||||
| Gross profit: | 992 | 835 | 1,420 | 755 | 839 | 873 | ||
| Operating expenses | (20,689) | (16,457) | (15,710) | (9,717) | (8,384) | (5,140) | ||
| Other undisclosed operating loss | (353) | |||||||
| Operating loss: | (20,050) | (15,622) | (14,290) | (8,961) | (7,545) | (4,267) | ||
| Nonoperating income (expense) | (7) | 12 | 3 | 20 | 12 | 12 | ||
| Investment income, nonoperating | 20 | 12 | 12 | |||||
| Other nonoperating income | 12 | |||||||
| Interest and debt expense | 159 | |||||||
| Loss from continuing operations: | (20,057) | (15,451) | (14,287) | (8,942) | (7,533) | (4,255) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (14,287) | (8,942) | (7,533) | (4,255) | |
| Net loss available to common stockholders, diluted: | (20,057) | (15,451) | (14,287) | (8,942) | (7,533) | (4,255) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (20,057) | (15,451) | (14,287) | (8,942) | (7,533) | (4,255) | ||
| Comprehensive loss, net of tax, attributable to parent: | (20,057) | (15,451) | (14,287) | (8,942) | (7,533) | (4,255) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.